Trial Profile
Efficacy and safety of enzalutamide in metastatic, castration-resistant prostate cancer (mCRPC) patients who were previously treated with docetaxel and abiraterone.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Nov 2015
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 19 Nov 2015 New trial record